Efficacy of trastuzumab

Cancer Research

Volumn 65, Issue 5, 2005, Pages 2044-

  Vogel, Charles L ^a   Reddy, Josina C ^b   Reyno, Leonard M ^b  

^a Cancer Research Network   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; LETTER; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; RADIOIMMUNOTHERAPY; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 16444373627     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3943     Document Type: Letter

References (5)

1. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A′-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200-6.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Genentech, Inc. Herceptin prescribing information: 2003.
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.